CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases
06 oct. 2021 08h00 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage Company focused on generating...
CENTOGENE’s Ground-Breaking Family Genetic Research Published in the New England Journal of Medicine Reveals Path to Potential Cure for Structural Birth Defects
29 sept. 2021 17h05 HE
|
CENTOGENE GmbH
Collaborative research utilized insights gained from CENTOGENE’s rare disease-centric Bio/Databank to help analyze data of more than 20,000 familiesEnabled testing of successful targeted therapeutic...
CENTOGENE Reports Second Quarter 2021 Financial Results
07 sept. 2021 06h35 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE to Announce Second Quarter 2021 Financial Results on September 7, 2021
01 sept. 2021 06h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Appoints Patrice P. Denèfle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development
27 juil. 2021 06h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting
25 juin 2021 06h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 25, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years
22 juin 2021 06h30 HE
|
CENTOGENE GmbH
Company outlines significant value creation potential to contribute to the diagnosis of rare diseases and to enable the development of novel therapeuticsFocuses on leveraging its unique rare...
CENTOGENE Reports First Quarter 2021 Financial Results in the Lead Up to Virtual Investor Event
16 juin 2021 06h30 HE
|
CENTOGENE GmbH
Recorded revenues of €65.0 million in Q1 2021, driven by revenues from COVID-19 testing, up over 400% compared to €12.1 million in Q1 2020Achieved positive adjusted EBITDA, driven by COVID-19 testing...
CENTOGENE to Announce Q1 2021 Financial Results on June 16, 2021
09 juin 2021 16h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 09, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Announces Virtual Investor Event
07 juin 2021 06h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 07, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...